1. Home
  2. ABUS vs CRAI Comparison

ABUS vs CRAI Comparison

Compare ABUS & CRAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.69

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo CRA International Inc.

CRAI

CRA International Inc.

HOLD

Current Price

$158.66

Market Cap

1.2B

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABUS
CRAI
Founded
2005
1965
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Consumer Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.2B
IPO Year
2008
1998

Fundamental Metrics

Financial Performance
Metric
ABUS
CRAI
Price
$4.69
$158.66
Analyst Decision
Strong Buy
Buy
Analyst Count
1
1
Target Price
$5.00
★ $245.00
AVG Volume (30 Days)
★ 4.7M
85.2K
Earning Date
05-14-2026
05-07-2026
Dividend Yield
N/A
★ 1.48%
EPS Growth
★ 55.26
20.77
EPS
0.84
★ 8.14
Revenue
$14,083,000.00
★ $751,583,000.00
Revenue This Year
N/A
$7.82
Revenue Next Year
$239.71
$5.14
P/E Ratio
★ $5.71
$20.23
Revenue Growth
★ 128.21
9.33
52 Week Low
$3.50
$132.17
52 Week High
$5.45
$227.29

Technical Indicators

Market Signals
Indicator
ABUS
CRAI
Relative Strength Index (RSI) 37.59 47.51
Support Level $4.42 $152.37
Resistance Level $4.81 $165.17
Average True Range (ATR) 0.09 5.17
MACD -0.05 0.03
Stochastic Oscillator 16.48 58.47

Price Performance

Historical Comparison
ABUS
CRAI

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

About CRAI CRA International Inc.

CRA International Inc is a consulting firm specializing in providing economic, financial and management consulting services. The company provides advisory services on economic and financial matters related to litigation and regulatory proceedings, and advises corporations on business and performance-related matters. Its consulting services are organized into two areas: litigation, regulatory and financial consulting, and management consulting. The company's clients include domestic and foreign companies, government agencies, public and private utilities, and national and international trade associations. It derives revenues by providing professional and consulting services. Geographically, the maximum revenue is derived from the United States, followed by United Kingdom and other regions.

Share on Social Networks: